Litchfield Hills analyst Theodore O’Neill initiated coverage of Inspira Technologies (IINN) with a Buy rating and $2 price target Inspira is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, the analyst tells investors in a research note. The firm says the company has a “well-protected technology moat” that includes both patented technology and technical trade secrets.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance
- Inspira Technologies Launches Global Rollout of ART100 System
- Inspira initiates global commercial rollout of ART100 system
- Inspira Technologies Restructures Executive Team for Strategic Alignment
- Inspira Technologies president Joe Hayon steps down